You are here: Industry Insights > Valeant Pharmaceuticals

News List

Valeant Pharmaceuticals Completes Sale Of iNova Pharmaceuticals americanpharmaceuticacreview
September 30, 2017
Valeant Pharmaceuticals has completed the sale of the iNova Pharmaceuticals business to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group for $930 million in cash.
Fund's $80B Valeant losses prompt lawsuit calling company a criminal enterprise fiercepharma
August 28, 2017
A new lawsuit brought by mutual fund Lord Abbett & Co. claims Valeant and former executives were engaged in a criminal scheme.
Valeant says it is getting on top of situation at troubled Bausch + Lomb plant tied to CRLs fiercepharma
August 18, 2017
Valeant Pharmaceuticals says that the FDA has noted improvements at its plant in Florida whose manufacturing issues have kept it from getting an approval for a new eye drug.
Valeant Pharmaceuticals to sell iNova business for $930m pharmaceutical-technology
June 13, 2017
Canadian company Valeant Pharmaceuticals International has entered an agreement to divest its iNova Pharmaceuticals business for $930m.
Valeant Pharmaceuticals Completes Sale of CeraVe, AcneFree and AMBI Skincare Brands to L'Oréal americanpharmaceuticalreview
March 07, 2017
Valeant Pharmaceuticals has completed the previously announced sale of its CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. Valeant will use net proceeds from the sale to permanently repay term loan debt under its Senior Cred
Valeant Pharmaceuticals and EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product americanpharmaceuticalreview
February 22, 2017
Valeant Pharmaceuticals International and EyeGate Pharmaceuticals have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive,